Search

Cardiovascular nuclear medicine (NM) imaging examinations expose patients to extremely high absorbed doses of ionizing radiation, which necessitates extensive efforts to reduce the doses without compromising the quality of images. This study aims to assess patients' radiation doses to patients and public exposure in Cardiac rest and stress single photon emission computed tomography (SPECT) scans. The patients' exposure was calculated for 21 patients using the administered activity (AA, MBq). (GE SPECT) was the device used for all patients. AA (MBq) mean and range were 370 for Rest and 1110 for Stress. The average range of the dose rate was 1.59 (0.67–2.34) mR/h for rest and 7.29 (4.2–9.98) mR/h for stress when computed at 30 cm from the patient's chest level after injection. At 100 cm from the patient, the mean dose rate values were 0.37 (0.16–0.73) mR/h for rest and 1.39 (1.01–2.0) mR/h for stress. The overall effective dose is 12.1 mSv per rest and stress SPECT procedure. The mean effective dose for cardiac rest is comparable with previously published studies while the effective dose from cardiac stress is higher than previously published studies. The variation in the effective dose depends on several factors, including the department's clinical indication imaging protocols and radiation safety measures. • The patient's effective dose and dose were quantified during cardiac rest and stress SPECT procedures. • The mean effective dose for cardiac rest is comparable with previously published studies. • The effective dose from cardiac stress is higher than previously published studies. • The current AA activity for rest and stress is lower than the DRL and the previous studies. [ABSTRACT FROM AUTHOR]

The objective of this study is to assess the patients' effective and organ dose during theranostic applications in Kuwait. In total, eighteen adults' patients were conducted nuclear medicine procedures with 177Lu Dotatate for theranostic purpose in Kuwait Cancer control center (KCCC), Kuwait. Medium energy collimator (MEC) (208 keV Scatter 26% better than 113 keV Scatter 60%) was utilized to obtain scans in definite time intervals ranged from one to 2 h (before voiding), 6:00, 24:00, 48:00, 72:00 h. Patients, tissue and organ radiation doses were computed utilizing OLINDA/EXM Software. The average radiation effective dose (in mSv/MBq) for bladder, liver, and both kidneys (left & right), were 0.36, 0.08, 0.61 & 0.60. The range of the effective dose was from 0.55 mSv to 7.7 mSv. The acquired scans using 177Lu were delivered diagnostic findings. The patients' effective dose is lower compared to the previous studies. Variation is attributed to the departmental protocol and administered activity. The values of the mean organ dose were comparable and lower than previously published studies. Different organs have different level of doses, which may affected by the presence of the metastatic tumors in the entire organ. • Patients' organs dosimetry in targeted radionuclide therapy were carried out in Kuwait Cancer Control Centre. • A total of 18 patients were undergone theranostic procedures with 177Lu Dotatate. • Organ and total patients doses were calculated using Organ Level INternal Dose Assessment (OLINDA) Software. • Optimization of the PET/CT imaging protocol is recommended to assure that patients received a minimal effective dose. [ABSTRACT FROM AUTHOR]

The positron emitters (18F-Sodium Fluoride (NaF)) and X-rays used in Positron emission tomography (PET) combined with computed tomography (PET/CT) imaging have a high radiation dose, which results in a high patient dose. The present research intends to determine the radiation dose and risks associated with PET/CT- 18F-Sodium fluoride examinations in patients. The 18F–NaF PET/CT was used to investigate the doses of 86 patients. Patient exposure parameters and ImPACT software were used to calculate mean effective doses. The administered activity of 185 MBq (5.0 mCi) per procedure has a mean and range based on the patient's BMI (BMI). The range of patient effective doses per procedure was found to be 4–10 mSv, with a radiation risk of 1 × 10−5 per procedure. Patient doses are determined by the patient's size, scanner type, imaging protocol, and reconstruction method. For further dose reduction, proper justification and radiation dose optimization is required. • Effective doses were estimated for patients undergoing PET/CT procedures. • CT contributed 66.7% to patient cumulative effective doses (mSv) while (18F–NaF, PET) contributed 33.3%. • Patients dose optimization is recommended during PET/CT examinations. [ABSTRACT FROM AUTHOR]

The objective of present study is estimation of the radioactivity held within the urinary bladder and kidneys 3 h post radiopharmaceutical (99mTc-MDP) administration, comparison being made via use of MIRDose. Using the conjugate-view method and built-in camera software Mediso XP Interview, urinary bladder and kidney radionuclide activities were calculated using patient clinical data acquired at the aforesaid 3 h post 99mTc-MDP injection juncture. The study was of a cohort of 40 patients attending for staging and cancer follow-up at the Nuclear Medicine Department, Royal Care International Hospital (RCIH), Sudan, Ethical and Research Committee approval for the study having been obtained. The radioisotope biokinetics were simulated using the Medical Internal Radiation Dose (MIRD) biokinetics model, specifically in regard to radionuclide activity in the kidneys and bladder. The results were compared with the data achieved via clinical study, showing the experimentally estimated radionuclide activity in the kidney to be greater by some 50% compared to that of simulation while the bladder radionuclide activity was found to be just 2% of the simulation result. The study also found that 0.9% of the administered radioactivity remained in the urinary bladder and kidneys 3 h post administration of the radionuclide, suggestive of low radiation dose to the urinary bladder and kidneys post 99mTc-MDP bone scans. • 99mTc-MDP radionuclide biokinetics were simulated using MIRD biokinetics model. • Radionuclide activities for Urinary bladder and kidney were calculated. • The experimentally estimated radionuclide activity in the kidney to be greater by some 50%. • 0.9% of the administered radioactivity remained in the urinary bladder and kidneys 3 h. • Low radiation dose to the urinary bladder and kidneys post 99mTc-MDP bone scans. [ABSTRACT FROM AUTHOR]